Humacyte, Inc. (NASDAQ:HUMA) Sees Significant Growth in Short Interest

Humacyte, Inc. (NASDAQ:HUMAGet Free Report) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 20,330,000 shares, an increase of 6.2% from the November 15th total of 19,140,000 shares. Approximately 19.6% of the shares of the company are sold short. Based on an average daily volume of 3,040,000 shares, the short-interest ratio is presently 6.7 days.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HUMA shares. Benchmark restated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. TD Cowen reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Thursday, November 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price target on shares of Humacyte in a report on Friday, September 20th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $13.00.

Read Our Latest Analysis on HUMA

Insider Activity at Humacyte

In other news, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the transaction, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at $7,615,889.60. The trade was a 13.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock worth $6,606,799 over the last quarter. Company insiders own 11.20% of the company’s stock.

Hedge Funds Weigh In On Humacyte

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its stake in Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after acquiring an additional 524,600 shares during the period. Thrivent Financial for Lutherans bought a new position in shares of Humacyte during the third quarter valued at approximately $712,000. Millennium Management LLC raised its stake in Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after buying an additional 1,334,641 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Humacyte by 62.7% during the second quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock worth $1,219,000 after buying an additional 97,931 shares during the period. Finally, AQR Capital Management LLC boosted its position in Humacyte by 1,018.4% during the 2nd quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock valued at $1,230,000 after acquiring an additional 233,422 shares in the last quarter. Institutional investors own 44.71% of the company’s stock.

Humacyte Trading Down 6.9 %

Shares of NASDAQ HUMA traded down $0.30 during trading hours on Tuesday, reaching $4.04. The stock had a trading volume of 1,058,081 shares, compared to its average volume of 2,409,834. The business’s fifty day moving average price is $4.96 and its two-hundred day moving average price is $5.93. The firm has a market cap of $508.47 million, a price-to-earnings ratio of -3.04 and a beta of 1.38. Humacyte has a 52-week low of $2.48 and a 52-week high of $9.97. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61.

Humacyte Company Profile

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Featured Articles

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.